Liver Cancer/HCC
Liver Cancer/HCC
EASL 2017: Generic Hepatitis C Drugs Continue to Produce High Cure Rates
- Details
- Category: Approved HCV Drugs
- Published on Monday, 01 May 2017 00:00
- Written by Keith Alcorn
Treatment with generic versions of direct-acting antiviral drugs (DAAs) for hepatitis C continues to produce similar cure rates to those reported in clinical trials of brand-name drugs, James Freeman reported last month at the EASL International Liver Congress in Amsterdam.
EASL 2017: Hepatitis C Treatment Allows 1 in 4 to Come Off Liver Transplant Waiting List
- Details
- Category: Liver Cancer/HCC
- Published on Monday, 01 May 2017 00:00
- Written by Keith Alcorn
Around a quarter of people with hepatitis C and decompensated cirrhosis came off liver transplant waiting lists in Europe after direct-acting antiviral (DAA) treatment, and very few had any subsequent liver-related problems during 15 months of follow-up, Luca Belli reported on behalf of the ELITA study investigators at the EASL International Liver Congress last month in Amsterdam.
EASL 2017: Switching to TAF for Hepatitis B Improves Kidney Function and Bone Loss
- Details
- Category: Approved HBV Drugs
- Published on Tuesday, 25 April 2017 00:00
- Written by Liz Highleyman
People with hepatitis B who switched from the old tenofovir disoproxil fumarate (TDF) to the new tenofovir alafenamide (TAF) saw improvements in kidney function biomarkers and recovery of bone loss, researchers reported at the EASL International Liver Congress last week in Amsterdam.
EASL 2017: EASL Releases Updated Hepatitis B Guidelines at International Liver Congress
- Details
- Category: HBV Treatment Guidelines
- Published on Tuesday, 25 April 2017 00:00
- Written by Liz Highleyman
The European Association for the Study of the Liver (EASL) presented revised clinical practice guidelines for the management of hepatitis B virus (HBV) infection -- the first update since 2012 -- during a special session at its International Liver Congress last week in Amsterdam. For the first time the guidelines include tenofovir alafenamide (TAF) and present evidence about when and how to stop antiviral therapy.
EASL 2017: Direct-Acting Antivirals for Hepatitis C Not Linked to Higher Liver Cancer Risk
- Details
- Category: HCV Disease Progression
- Published on Thursday, 20 April 2017 00:00
- Written by Liz Highleyman
Hepatitis C patients treated with direct-acting antivirals (DAAs) do not appear to have a higher risk of developing liver cancer compared to those treated with interferon, and the seemingly higher rates seen in some studies are attributable to risk factors such as older age and more advanced liver disease, according to a set of studies presented at the EASL International Liver Congress this week in Amsterdam.
More Articles...
- EASL 2017: Nivolumab Increases Survival for People with Advanced Liver Cancer
- CROI 2017: Are HIV/HCV Coinfected People Cured with DAAs at Increased Risk for Liver Cancer?
- AASLD 2016: Nivolumab Shows Good Safety and Promising Response Rates in Liver Cancer Study
- Coverage of the 2016 AASLD Liver Meeting
Web Design and Development by